About our Studies
Dr. Klapper is now seeing private patients
Our staff is committed to providing the highest level of care for our patients. We provide a comfortable and safe clinical environment where patients and their caregivers can participate in the latest in medical research for their condition.
Mile High Research Center is involved in Phase II, III and IV Double Blind, Placebo-Controlled Clinical Trials to investigate the safety and efficacy of investigational medications for the treatment of neurological diseases, focusing on Alzheimer's Disease. These trials are rigorously monitored by the FDA and by the pharmaceutical companies conducting the trials in order to protect participants' health and well being.
Please see our "In the News" page for more information about our currently enrolling studies.
What Everyone Should Know About Clinical Trials
To qualify for our clinical trials, you do not need to have received a diagnosis of Probable Alzheimer's Disease. If you are experience memory issues, or you have a family history of Alzheimer's Disease, you may qualify for a research study.
Being part of a clinical study is supplemental to any routine medical care that the patient receives from their Primary Care Physician or Neurologist.
Enrolling in a clinical trial is at no cost to the patient or the caregiver.
Clinical trials are fully financially supported by the pharmaceutical company responsible for researching the investigational medication. Safety procedures included for every patient in the trials include:
Regular ECGs to monitor heart healthRoutine blood work and urine testing to ensure normal chemistry in the fluid of the body, frequent MRIs (if required by study protocol) to monitor brain health, physical and neurological examination at every visit to ensure safety for the patient.
Prescreening procedures ensure that the patient is matched to the right study for their medical needs.
A caregiver who sees the participant regularly and is aware of intimate details about the participant's health (such as eating and sleeping habits) is a requirement in all of our studies. Caregivers must accompany the patient to the first visit to Mile High Research Center and at certain intervals during the study.
Many of our studies provide the patient the option of an open-label portion of the trial after the initial visits are completed. This provides the opportunity for the patient to receive the investigational treatment at no cost until the completion of the study.